Twitter

latest news

  • Interface Biologics and Q3 Medical Devices Sign Agreement to Develop Next Generation Drug Coated Balloon with Kinesyx™ Technology

    TORONTO, ONTARIO--(Marketwired - Jan. 14, 2014) - Interface Biologics Inc. (IBI), and Q3 Medical Devices Limited are pleased to announce the signing of a joint development and commercialization agreement to combine IBI's Kinesyx bioactive...

    Read more...
  • AngioDynamics Extends Licensing Agreement With Interface Biologics to Include Central Venous Catheters

    AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, and Interface Biologics Inc. (IBI), a privately-held commercial stage developer of transformative biomedical-polymer products, announced AngioDynamics'...

    Read more...
  • Technology from IBBME spin-off Interface Biologics Inc. receives 2nd nod from FDA

    Interface Biologics, Inc, the spin-off company begun by Professor Paul Santerre, has received its second FDA clearance in less than a year for AngioDynamic’s BioFlo Port catheter.

    Read more...
  • AngioDynamics Earns FDA Clearance for Ports With BioFlo Technology to Reduce Catheter-Related Thrombus

    Read more...
  • Premier Selects AngioDynamics' BioFlo PICC as a Breakthrough Technology

    BioFlo Technology Highlighted During Fifth Annual Innovation Celebration

    Read more...
  • Interface Biologics Appoints Sandra Beach Lin to Board of Directors

    Interface Biologics Inc. (IBI), a privately held commercial stage developer of transformative biomedical-polymer products, is pleased to announce the appointment of Sandra Beach Lin to the Board of Directors.

    Read more...
  • Medical device clears regulatory hurdle in the United States

    What began in the Dentistry lab of Professor Paul Santerre more than a decade ago is now Interface Biologics Inc. (IBI) - a privately-held company poised to transform the market for medical devices in the United States.

    Read more...
  • Interface Biologics announces Licensing Partner AngioDynamics has received FDA Clearance for BioFloTM PICC with EndexoTM Technology

    Read more...
  • Many strengths and assets that Ontario's diverse life sciences sector has to offer.

    Interface Biologics a part of Life Sciences Ontario (LSO) promotional video showcasing the many strengths and assets that Ontario's diverse life sciences sector has to offer.

    Read more...
  • Interface Biologics Announces $1 Million Investment By Ontario’s Investment Accelerator Fund – Life Sciences

    Toronto, Canada, December 6, 2011 – For Immediate Release

    Interface Biologics Inc. (IBI), a privately held commercial stage developer of transformative biomedical-polymer products, announces a $1 million investment ...

    Read more...
  • Interface Biologics announces Licensing Agreement with Navilyst Medical

    Toronto, Canada, October 25, 2011 – For Immediate Release

    Interface Biologics Inc. (IBI), a privately held commercial stage developer of transformative biomedical-polymer products, is pleased to announce ...

    Read more...
  • Fresenius Medical Care Executes Exclusive Interface Biologics License Agreement

    Toronto, Canada, July 12, 2011 – For Immediate Release

    Interface Biologics Inc. (IBI), a privately held commercial stage developer of transformative biomedical-polymer products, is pleased to announce ...

    Read more...
  • Interface Biologics Announces New VP Finance

    Toronto, Canada, May 31, 2011 – For Immediate Release

    Interface Biologics Inc. (IBI), a privately held commercial stage developer of transformative biomedical-polymer products, is pleased to announce ...

    Read more...
  • Interface Biologics Appoints Art Rosenthal to Chairman of its Board of Directors

    Toronto, Canada, February 14th, 2011 – For Immediate Release

    Interface Biologics Inc. (IBI), a privately held commercial stage developer of transformative biomedical-polymer products, is pleased to announce ...

    Read more...
  • Interface Biologics Financing Deal Gives A New Face to Biomedical Polymer Technology

    At work developing transformative biomedical-polymer products, Interface Biologics, a private company, has recently completed a $7M series B financing led by Business Development Bank of Canada in conjunction with Covington Capital and VG Partners.

    Read more...
  • Interface Biologics - BASF Future Business Collaborate

    Toronto, Canada, January 4, 2011 - For Immediate Release

    Interface Biologics Inc. (IBI), a privately held commercial stage developer of transformative biomedical-polymer products, is pleased to announce the…

    Read more...
  • Interface Biologics Receives ISO 13485:2003 Certification


    Toronto, Canada, October 26, 2010 – For Immediate Release

    Interface Biologics Inc. (IBI), a privately held early commercial stage developer of transformative biomedical-polymer technology…

    Read more...
  • U of T is helping to create a culture of innovation

    Dentistry professor Paul Santerre understands the world of start-up companies. Ten years ago, well before assuming his current role as director of the Institute…

    Read more...
  • Interface Biologics – Fresenius Medical Care Sign License Agreement


    Toronto-- July 20, 2010 --Interface Biologics Inc. (IBI), a privately held early commercial stage developer of transformative biomedical-polymer technology products, is pleased to announce…

    Read more...
  • Interface Biologics Inc’s Chief Scientific Officer Wins Julia Levy Award

    Toronto, Canada, March 5, 2010 - For Immediate Release

    Interface Biologics Inc. (IBI), a privately held developer of transformative bio-medical polymer technology that improves the…

    Read more...

photo

INTERFACE BIOLOGICS, INC. (IBI) is a privately held early commercial stage company that develops transformative biomedical polymer technology to improve the safety and effectiveness of medical devices.

Our primary technology focus areas are anti-thrombogenic additives that reduce thrombosis and programmable combination drug delivery devices.

The company was founded in 2001 based on the work of Dr. Paul Santerre at the University of Toronto. The name, Interface Biologics, comes from the critical interface between the human body and medical devices at the molecular level.

Powered by Innovasium